Navigation Links
AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
Date:8/29/2007

CASTLE ROCK, Colo., Aug. 29 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, reported today the company has been invited to present at the annual Roth Capital Partners New York Investor Conference to be held September 5 and 6, 2007. More than 1,200 institutional investors are expected to attend the conference, which will be held at the Westin New York at Times Square.

AspenBio's CEO Richard Donnelly is scheduled to present on Thursday, September 6, at 2:00 P.M. Eastern Time. A simultaneous Webcast will be available at: http://www.wsw.com/webcast/roth13/apnb.ob.

Mr. Donnelly will discuss progress of AspenBio key products, including a specialized assay that detects a marker in the blood associated with appendicitis. According to three studies conducted during the past 33 months, including an ongoing 400 patient study, the company's AppyScore(TM) blood test has been able to identify patients with appendicitis at a very high sensitivity level of 94% to 97%. This compares to significantly lower diagnostic success rates for expensive CT scans, which are generally considered the best diagnostic method currently available for appendicitis. With the AppyScore emergency room triage test and its sister product, AppyScreen(TM), designed for physician offices, AspenBio is targeting a significant need for more economical, accurate and faster assessment of the appendicitis condition.

Roth Capital Partners Stock Conferences are among the largest in the nation for micro and small-cap companies in the technology,
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
(Date:7/10/2014)... disorders has been extremely challenging because there are many ... to cause disease. Now investigators reporting in the July ... Stem Cell describe a strategy that may help ... risk factors or environmental exposures to affect the development ... variant that may predispose individuals to schizophrenia. , ...
(Date:7/10/2014)... by researchers at the University of Illinois at ... governing the interplay of spin and heat at ... ultrafast spintronic devices for data storage and information ... well as spin-angular momentum. In a typical charge ... no spin current," explained David Cahill, a professor ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2University of Illinois study advances limits for ultrafast nano-devices 2
... -- bioTheranostics, a bioMerieux company that develops ... announced today study results published in the next issue ... to the clinical validity and the clinical utility of ... in the determination of the origin of a tumor. ...
... 2011 Peloton Therapeutics, Inc., an early-stage cancer drug ... an $18 million Series A financing.  Led by The ... O,Donnell, Jr., the Series A funds supplement a recently ... Research Institute of Texas (CPRIT). Peloton officials ...
... 2011 The Raymond and Ruth Perelman ... announces the launching of a first-of-its-kind interdisciplinary ... diseases. The Center will bring together, without institutional ... orphan diseases: establishing dedicated research support facilities, translating ...
Cached Biology Technology:New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 2New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 3Peloton Therapeutics Completes $18 Million Series A Financing 2Peloton Therapeutics Completes $18 Million Series A Financing 3Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy 2
(Date:7/11/2014)... have set a "mouse TRAP" to capture the early ... study published in the Journal of Clinical Investigation ... called TRAP to extract cellular and genetic information from ... at the Rockefeller Institute for Medical Research in 2008, ... machinery, or ribosomes, of the cell type of interest. ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... millipedes previously unknown in Australia has been discovered by ... of the widespread tropical family Pyrgodesmidae have been found among ... are not only widespread in Australia,s tropical and subtropical ... been published in the open access journal ZooKeys ...
... Trust and the Engineering and Physical Sciences Research Council ... initiative to find biomedical engineering solutions to challenging healthcare ... provide funding for a limited number of ground-breaking long-term ... are inadequate. Up to 10m over seven years is ...
... 29, 2012 The Crop Science Society of America (CSSA) ... during their Annual Meetings, Oct. 21-24, 2012 in Cincinnati, OH. ... professional achievements and meritorious service. Only 0.3 percent of the ... 2012 class of CSSA Fellows are: Marc C. ...
Cached Biology News:Millipede family added to Australian fauna 2£30 million boost for biomedical engineering research 2Crop Science Society of America presents 2012 class of fellows 2Crop Science Society of America presents 2012 class of fellows 3
... Agarose Spin Kit is an advanced system for isolating ... DNA can be used directly for any downstream application. ... is ready to use in 56 minutes Low ... for TAE and TBE gels No specialised equipment ...
... Spin Columns provide a rapid and simple method ... bp to 10 kb) from stained agarose gels ... excised from an agarose gel and loaded into ... the column are a series of membranes and ...
... Silica Bead Kit has been designed for recovery of ... Features Ultra fast protocol: DNA ... silica beads are easy to resuspend Bead uniformity ... pure DNA (suitable for PCR) DNA is eluted ...
... extraction of DNA fragments from 150 bp to > ... uses GelMelt solution to dissolve the gel slice, followed ... in a spin column format. After a wash step, ... spin column can bind up to 20 g DNA. ...
Biology Products: